Announced
Teoxane to acquire the remaining shares in Revance Therapeutics at a $375m valuation.
Synopsis
Teoxane, a privately-held company in the global medical aesthetics sector, agreed to acquire the remaining shares in Revance Therapeutics, a biotechnology company focused on innovative aesthetic and therapeutic offerings, at a $375m valuation.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Bidder Team (12)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite